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The highly heterogenous Gram-positive bacterium Streptococcus (S.) suis poses a major burden to 
the pig industry (SELBITZ et al. 2015, GOTTSCHALK 2012). Meningitis, arthritis, serositis and 
endocarditis are main pathologies observed in connection with S. suis disease in swine. Most 
commonly, piglets are affected in their 5th to 10th week of life (GOTTSCHALK 2012), though cases of 
acute disease have also been reported from pigs outside this age group (WISSELINK et al. 2000, 
BOETNER et al. 1987). As a member of the Streptococcus genus, S. suis colonizes mucous 
membranes, e.g. of the respiratory and reproductive tract (AMASS et al. 2000, FERRANDO et al. 
2010, CLOUTIER et al. 2003). Accordingly, 100% of the pigs in commercial animal husbandry are 
considered carriers of S. suis (GOTTSCHALK 2012). The main host of S. suis is the pig but it is also a 
known zoonotic agent as human cases of S. suis disease occur, especially in Asian countries (ARENDS 
and ZANEN 1988, YE et al. 2006, LUN et al. 2007). People with contact to pigs and raw pork products 
are at a higher risk to fall ill with S. suis disease (ARENDS and ZANEN 1988, HUANG et al. 2005). Most 
human cases are caused by S. suis serotype 2 which is overall considered the most prevalent 
serotype worldwide (GOYETTE-DESJARDINS et al. 2014). However, in Europe serotypes like 7 and 9 
are also highly prevalent in cases of S. suis disease (GOYETTE-DESJARDINS et al. 2014). With at least 
29 serotypes (PERCH et al. 1983, GOTTSCHALK et al. 1989, GOTTSCHALK et al. 1991, HIGGINS et al. 
1995, GOYETTE-DESJARDINS et al. 2014) and numerous described virulence (-associated) factors 
(FITTIPALDI et al. 2012, SEGURA et al. 2017), this pathogen is highly diverse and prophylaxis is 
challenging. To date, there is no commercially produced vaccine available in Europe to prevent S. suis 
disease (SEGURA 2015), thus this bacterium is responsible for major economic losses of pig raising 
farms in European countries. At present, the only opportunity to prevent S. suis disease is the use of 
autogenous vaccines (HAESEBROUCK et al. 2004). Experimental studies have only demonstrated 
protection of serotype 2 bacterins against homologous challenge (BAUMS et al. 2009, WISSELINK et 
al. 2001). The protective efficacy of other bacterins consisting of for example serotypes 9 and 7 is 
moderate or poor (BÜTTNER et al. 2012, UNTERWEGER et al. 2014) or has not been investigated. 
Moreover, predisposing factors such as the porcine reproductive and respiratory syndrome virus 
(PRRSV) may influence the protective efficacies of bacterins (HALBUR et al. 2000). Recently, vaccine 
research has focused on subunit vaccines as these have the potential to confer cross-protection 
between serotypes (SEGURA 2015). Experimental studies have for example investigated protective 
efficacies of three virulence (-associated) factors: the muramidase-released protein (MRP), the 
extracellular factor (EF) (WISSELINK et al. 2001) and suilysin (SLY) (JACOBS et al. 1996) with varying 
success. In 2013, Dr. Jana Seele discovered the highly specific immunoglobulin M-degrading enzyme 
of S. suis, IdeSsuis (SEELE et al. 2013) and showed that this protein was highly protective against a 
serotype 2 challenge (SEELE et al. 2015b). This was a very encouraging result with regard to the 
development of a S. suis vaccine. However, so far only homologous protection was shown. To prove 
heterologous protection, experimental models with serotypes other than serotype 2 are needed but 
are scarce to date. 
In this thesis, neglected but important invasive S. suis pathotypes of serotypes 7 and 9 were 
characterized and a new infection model in the main host of S. suis, the pig, was established. The 




finally immunogenicities and protective efficacies of IdeSsuis vaccination were evaluated in a serotype 





2.1 Streptococcus suis 
2.1.1 Classification and Characteristics 
Streptococcus is a genus of Gram-positive spherical or ovoid bacteria physiologically colonising 
mainly the skin and mucous membranes, but some pathogenic species might cause severe disease in 
animals and humans. They are differentiated based on biochemical reactions, haemolytic activity and 
serologic specificity (PATTERSON 1996, SELBITZ et al. 2015). S. suis is a facultatively anaerobic and on 
sheep blood agar α-haemolytic coccus with at least 29 serotypes (PERCH et al. 1983, GOTTSCHALK et 
al. 1989, GOTTSCHALK et al. 1991, HIGGINS et al. 1995, GOYETTE-DESJARDINS et al. 2014) described 
to belong to Lancefield groups R, S, RS, T or D (DE MOOR 1963, FACKLAM 2002). This Lancefield 
classification is, however, not reliable for S. suis and therefore should not be used (HIGGINS and 
GOTTSCHALK 1990, GOTTSCHALK et al. 2010). S. suis inhabits the upper respiratory tract and 
intestines of pigs (DEVRIESE et al. 1994) and has also been recovered from vaginal swabs (AMASS et 
al. 1995). Mainly growers from 5 to 10 weeks of age are affected by S. suis disease (GOTTSCHALK 
2012), but isolation of S. suis from the tonsils of healthy carrier pigs of various ages is very common 
(LUQUE et al. 2010). Some serotypes are associated with disease at a certain age, such as serotype 1, 
which was mostly isolated from 3-week-old pigs (WISSELINK et al. 2000). It is widely known that the 
carrier status of S. suis in swine herds is almost 100% (GOTTSCHALK 2012) and most pigs carry more 
than one serotype (FLORES et al. 1993). Humans can also be affected by this emerging zoonotic 
pathogen and may develop meningitis, arthritis or endocarditis and in some cases streptococcal toxic 
shock-like syndrome (STSS) (ARENDS and ZANEN 1988, YE et al. 2006, LUN et al. 2007, GOYETTE-
DESJARDINS et al. 2014). S. suis carries many virulence (-associated) factors and continuously more 
are discovered. The best characterized among these factors are the hemolysin SLY, MRP and the 
capsular polysaccharide (CPS). Of these, only the CPS is accepted as a critical factor in S. suis 
virulence (SEGURA et al. 2017). Recently, virulence was associated with the length of the genome of 
S. suis strains. Zoonotic strains were shown to have smaller genomes than non-zoonotic strains but 
to carry more virulence (-associated) factors (WEINERT et al. 2015, WILLEMSE et al. 2016).  
 
2.1.2 Diagnostics 
S. suis grows on sheep blood agar with grey to white glossy colonies surrounded by α-haemolysis. 
Some strains show ß-haemolysis on horse blood agar (HOMMEZ et al. 1986, FACKLAM 2002). Gram 
staining reveals Gram-positive single cocci, diplococci or short chains (CLIFTON-HADLEY and 
ALEXANDER 1988). Species diagnosis can either be obtained through serological or biochemical tests, 
matrix-assisted laser desorption/ ionisation time of flight mass spectrometry (MALDI-TOF MS) or 
detection of the S. suis specific glutamate dehydrogenase gene (gdh) or the gene encoding a 
recombination/ repair protein (recN) by polymerase chain reaction (PCR) (CLIFTON-HADLEY and 
ALEXANDER 1988, OKWUMABUA et al. 2003, LE TIEN et al. 2013, PÉREZ-SANCHO et al. 2015, PRÜFER 
et al. 2019). For detection of genes encoding different virulence (-associated ) factors of S. suis 
including capsular polysaccharide synthesis loci (cps), specific for each serotype, PCRs have been 




as serotypes 1 and 14 as well as 2 and 1/2 cannot be distinguished. In those cases serum 
agglutination (BAUMS and VALENTIN-WEIGAND 2009, SMITH et al. 1999, GOYETTE-DESJARDINS et al. 
2014) or sequencing of the glycosyltransferase gene cpsK (ROY et al. 2017) has to be conducted. In 
addition to serotyping, sequence typing of seven housekeeping genes (cpn60, thrA, recA, aroA, dpr, 
gki and mutS) of S. suis has been developed representing a method easily standardized between 
different laboratories (KING et al. 2002). This multilocus sequence typing (MLST) allows for seven 
selected housekeeping genes to be assigned individual allele numbers. The combination of these 
seven allele numbers results in a sequence type (ST). One ST may include several serotypes, on the 
other hand strains of one serotype can belong to different STs. Data is shared in an online database 
available at pubmlst.org. So far, 1,308 STs (June 04, 2020) have been described and continuously 
more are added. Generally, in contrast to serotyping, sequence typing correlates with genetical 
relations of S. suis strains (KING et al. 2002). 
 
2.1.3 Prevalence of S. suis sero- and sequence types in North America, Europe and Asia 
Of all S. suis serotypes, most information is available on serotype 2, accordingly the best investigated 
serotype. Worldwide, distribution of S. suis in pigs and humans was reviewed some years ago but up-
to-date information from outside North America was non-existent (GOYETTE-DESJARDINS et al. 
2014). Very recently, two articles on S. suis distribution from North America (mainly USA) and 
Germany have been published uncovering changes in serotype prevalence in the past years (PRÜFER 
et al. 2019, ESTRADA et al. 2019). Overall, serotype 2 is described as the predominant serotype 
isolated from diseased pigs and humans worldwide (WISSELINK et al. 2000, GOYETTE-DESJARDINS et 
al. 2014). However, there are notable geographical differences and information is not evenly spread. 
Thus, 70% of the epidemiological data is from North America, with 97% of it from Canada and 3% 
from the USA (GOYETTE-DESJARDINS et al. 2014). Whereas GOYETTE-DESJARDINS et al. (2014) have 
summarized serotype 2 to be the predominant serotype followed by serotype 3 in Canada and 
reversely in the USA, data collected from 2014-2017 presented itself differently with serotype 1/2 
dominating over serotype 7 in North America (mainly USA) followed by serotypes 2 and 1 (ESTRADA 
et al. 2019).  
Distribution of serotypes in seven European countries was investigated by WISSELINK et al. (2000) for 
S. suis strains isolated before 1997. For Italy, France, Belgium and the UK this is the latest available 
study. Accordingly, serotypes 2, 1 and 9 are mainly isolated from diseased pigs in Italy, whereas in 
France serotype 2 is the most prevalent followed by serotypes 7 and 9. In Belgium serotype 9 
predominates, followed by serotype 2, and finally serotype 1 is isolated the most in the UK followed 
by serotypes 2 and 14 (WISSELINK et al. 2000). Recently published data from Germany revealed a 
predominance of serotypes 2 and 1/2 followed in decreasing order by serotypes 9, 7, 4 and 8. 
Serotypes 2 and 1/2 were not distinguished in this study as differentiation relied on genotyping of 
cps genes only (PRÜFER et al. 2019). In Spain and the Netherlands serotype 9 is the most prevalent 
(VELA et al. 2003, TARRADAS et al. 2004, SCHULTSZ et al. 2012). In Denmark, serotype 7 is a very 
important serotype (AARESTRUP et al. 1998, TIAN et al. 2004). There is no information on S. suis 
causing disease in Polish pigs but some human cases have been described indicating dominance of 




reported from Asia (mainly China, Vietnam and Thailand), available data on diseased pigs from this 
continent is scarce. However, from what is known, serotype 2 is also predominant in Asia followed by 
serotypes 4, 7 and 8 (GOYETTE-DESJARDINS et al. 2014) and in China serotype 9 is also prevalent (WU 
et al. 2008). A couple of human cases caused by serotype 14 have been described in Thailand 
(KERDSIN et al. 2011). 
Regarding STs, a great diversity in porcine isolates has been shown (VELA et al. 2003), in contrast to 
human isolates which mainly belong to only very few STs. Illustrating the whole S. suis MLST 
database in an eBURST diagram, ESTRADA et al. (2019) showed that the current data reveals only five 
clonal complexes (CCs): 1, 28, 94, 104 and 750, when using the strictest definition of a CC (only single 
locus variants (SLV) of a ST are included). Virulent isolates associated with disease in animals as well 
as in humans often belong to ST1, the founder of CC1 (KING et al. 2002, GOYETTE-DESJARDINS et al. 
2014). This also applies to invasive European serotype 2 isolates which mostly belong to ST1. 
However, in the Netherlands serotype 2 of ST20 was also associated with disease in humans. Further, 
S. suis serotype 9 is of great importance in some European countries and often belongs to ST16 and 
ST61 which are especially prominent in the Netherlands and Spain, respectively (BLUME et al. 2009, 
SCHULTSZ et al. 2012). Interestingly, even though serotype 9 isolates in Europe mainly belong to ST16 
(SCHULTSZ et al. 2012), a human case of serotype 9 (of CC16) infection has only been described once 
(KERDSIN et al. 2015). In contrast to previous work, in North America ST28 and 25 are no longer 
predominant, but now it is ST28 followed by ST94, 1 and 108 (FITTIPALDI et al. 2011, ESTRADA et al. 
2019). A large scale outbreak of human S. suis cases in Sichuan province, China, in 2005 which caused 
38 deaths was due to a serotype 2 strain of ST7, a SLV of ST1 (YE et al. 2006). ST 103 and 104 have 
only been described from human cases in Thailand, where otherwise ST1 predominates 
(TAKAMATSU et al. 2008, KERDSIN et al. 2011).  
In summary S. suis serotype 2 and ST1 are still considered to be the most prevalent associated with 
disease in pigs and humans worldwide. However, distribution has changed over time, and regional 
differences are present. Especially North American isolates seem to differ from those isolated in 
Eurasia. Up-to-date information is lacking from many countries. This applies particularly to data from 
diseased pigs, the main disease vectors.  
 
2.1.4 Pathogenesis 
The pathogenesis of S. suis infection is not yet fully understood, though knowledge has improved 
since human cases have increased especially in Asian countries (WERTHEIM et al. 2009, DORAN et al. 
2016). To understand the change of the colonizing bacterium S. suis to an invasive pathogen causing 
severe disease or even death, the numerous described virulence (-associated) factors have to be 
considered. Many virulence factors or factors associated with virulence and their role during 
pathogenesis have been reviewed (FITTIPALDI et al. 2012, BAUMS and VALENTIN-WEIGAND 2009) 
and the definition of critical virulence factors as unique with a precise role during pathogenesis has 
been proposed (SEGURA et al. 2017).  
Colonization of the upper respiratory tract represents the first step of pathogenesis. It occurs after 
nasal or oral exposure (AMASS et al. 2000, FERRANDO et al. 2010, TANIYAMA et al. 2016). Vaginal 




contact account for horizontal transfer (CLOUTIER et al. 2003). The surface-located amylopullulanase 
(ApuA) binds to porcine mucous in vitro and thus is supposed to play a role in colonization in vivo 
(FERRANDO et al. 2010). The contribution of other adhesins located on the surface of S. suis such as 
the fibronectin-binding enzyme enolase (ESGLEAS et al. 2008) or the glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) (BRASSARD et al. 2004) requires further investigation (FITTIPALDI et al. 
2012). Immunoglobulin (Ig) M and especially IgA are important mucosa-associated components of 
the host defence (BRADLEY et al. 1976, DORAN et al. 2016). S. suis possesses the highly specific 
IdeSsuis to evade parts of the host immune system (SEELE et al. 2013). A specific IgG protease of 
S. suis, designated IgdE, has also been described recently (SPOERRY et al. 2016). Further factors to 
evade host defence mechanisms are the two desoxyribonucleases SsnA (the S. suis secreted nuclease 
A) and the endonuclease A of S. suis (EndAsuis). Both enzymes are able to degenerate neutrophil 
extracellular traps (NETs). Their definitive role in pathogenesis of S. suis disease remains to be 
elucidated (DE BUHR et al. 2014, DE BUHR et al. 2015). The CPS is an accepted critical virulence factor 
as it clearly contributes to the virulence of S. suis strains by protecting the bacterium from 
phagocytosis (SMITH et al. 1999, ROY et al. 2015). The capsule is supposed to partially mask adhesins 
and integrins (LALONDE et al. 2000), thus unencapsulated strains adhere and invade epithelial cells 
better than encapsulated strains (BENGA et al. 2004). Up- and downregulation of the capsule 
depending on the stage of infection is a common hypothesis (GOTTSCHALK and SEGURA 2000, 
FITTIPALDI et al. 2012).  
Breaching the epithelial barrier defines the next step in S. suis pathogenesis which is also not fully 
disclosed. The thiol-activated and secreted hemolysin SLY has a cytotoxic effect on epithelial cells 
(NORTON et al. 1999). Accordingly, SLY+ strains may use destruction of the epithelial barrier rather 
than invasion of the cells to reach the blood stream (LALONDE et al. 2000). Nonetheless, a serotype 2 
suilysin deletion mutant strain has been isolated from experimentally infected animals including 
isolation of the strain from the brain of one pig, proving that it is not essential for virulence and 
invasion of the host (ALLEN et al. 2001). After breaching epithelial barriers, S. suis has to survive in 
the bloodstream in order to disseminate and establish infection in the host. Different qualities of 
S. suis contribute to this. First of all, the CPS and SLY again play a role by protecting the bacterium 
from phagocytosis (FITTIPALDI et al. 2012, CHABOT-ROY et al. 2006, BENGA et al. 2008). 
Furthermore, molecular mimicry is proposed, as parts of the capsule mimic sugar epitopes present 
on the surface of all mammalian cells and hence recognition by the host immune system is hampered 
(FITTIPALDI et al. 2012). In addition, modification of the bacterial cell wall by N-deacetylation of 
peptidoglycan (FITTIPALDI et al. 2008a) or D-alanylation of lipoteichoic acid (LTA) (FITTIPALDI et al. 
2008b) leads to resistance to neutrophil killing through resistance to lysozyme and cationic 
antimicrobial peptides (CAMP). In case of internalization by phagocytes and thus acidic stress, the 
arginine deiminase system (ADS) of S. suis can neutralize the acidic intraphagolysosomal pH by 
converting arginine to ornithine, ammonia and carbon dioxide generating adenosine triphosphate 
(ATP) and thus improving intracellular survival (GRUENING et al. 2006, DORAN et al. 2016, FULDE et 
al. 2011). MRP and enolase have been shown to interact with human fibrinogen and promote 
antiphagocytosis and thus survival in human blood (PIAN et al. 2015). A similar anti-phagocytic effect 




Entering internal organs marks the last step of S. suis pathogenesis. Most research in this regard has 
focused on the central nervous system (CNS). To induce meningitis, S. suis has to traverse the blood 
brain barrier (BBB), composed of a monolayer of brain microvascular endothelial cells (BMEC) and/ 
or the blood cerebrospinal fluid barrier (B-CSFB), composed of two cell layers, a fenestrated 
endothelial and a choroid plexus epithelial cell (CPEC) layer (DORAN et al. 2016). S. suis has been 
shown to adhere to and invade porcine BMECs at least in vitro (VANIER et al. 2004) though no 
evidence of invasion was found in a model with human BMECs (CHARLAND et al. 2000). Many 
mechanisms which are found to play a role in crossing of the epithelial barrier in the first steps of 
S. suis infection are also of importance when it comes to entering the brain. For example, there is 
agreement on the cytotoxic effect of SLY on BMECs and accordingly that SLY contributes to crossing 
of the BBB in studies on human or porcine BMECs (CHARLAND et al. 2000, VANIER et al. 2004). D-
alanylation of LTA plays a role in adherence to and invasion of porcine BMECs, as a ∆dltA mutant 
showed significantly less adherence and invasion of the BMECs (FITTIPALDI et al. 2008b). Different 
proteins with a leucine-proline-X (variable)-threonine-glycine (LPXTG)-motif may be part of the 
adhesion and invasion process of porcine BMEC. A mutant deficient in sortase A, a transpeptidase 
responsible for covalent bonds of proteins to the bacterial cell wall via the LPXTG-motif, showed 
decreased adhesion to and invasion of porcine BMECs (VANIER et al. 2008). One of the substrates of 
sortase A is the LPXTG-motif containing MRP. Its function has been described as binding human 
fibrinogen (PIAN et al. 2015). In a mouse meningitis model, wild type S. suis induced more severe 
histopathological lesions and an increased permeability of the BBB than the MRP-deficient mutant. 
An increased adherence to and traversal of human BMECs through interaction of MRP and human 
fibrinogen was also demonstrated in vitro (WANG et al. 2015). Additionally, the sialic acid, one 
component of the polysaccharide capsule of serotypes 1, 2, 14, 27 and 1/2 (SMITH et al. 2000), might 
contribute to adherence to monocytes without phagocytosis, using them as a vehicle to travel 
through the blood and even through the BBB, according to the so-called modified Trojan horse theory 
(GOTTSCHALK and SEGURA 2000, GOTTSCHALK et al. 2010).  
S. suis is able to induce cytokine production in phagocytes and cell wall components are supposed to 
contribute to this (SEGURA et al. 1999). Sometimes the result is an excessive inflammatory response 
and finally a toxic shock as described for porcine and human S. suis disease (FITTIPALDI et al. 2012). 
BMECs and CPECs also upregulate their cytokine production, including interleukin (IL)-6 and IL-8, 
upon S. suis infection probably due to bacterial cell adhesion. Thereby the permeability of the BBB 
and the B-CSFB may be increased (VADEBONCOEUR et al. 2003, SCHWERK et al. 2011). The B-CSFB 
thus marks another entry site of S. suis to the brain. It has been shown that the bacterium enters 
CPECs from the basolateral (blood) side. S. suis is able to induce cell death of CPECs in vitro, 
promoting the traversal of the bacterium but may also translocate through intact CPECs 
(TENENBAUM et al. 2006, TENENBAUM et al. 2009).  
Knowledge on the pathogenesis of S. suis disease has substantially increased since this pathogen has 
turned out to be a threat for porcine and also human health. However, further studies are needed to 





2.1.5 Streptococcus suis disease in swine and humans 
Meningitis, arthritis, endocarditis, (poly-) serositis, bronchopneumonia and septicaemia are known 
pathologies of S. suis infection in pigs which are primarily affected at an age of 5 to 10 weeks. The 
carrier rate is up to 100% and notably higher in young (5 weeks) than in older (20 weeks) pigs 
(GOTTSCHALK 2012, SELBITZ et al. 2015). Furthermore, investigation of Chinese and UK isolates has 
revealed that high ambient temperatures are associated with higher isolation rates (ZOU et al. 2018). 
Carrier pigs are an important source of S. suis infection as they might carry potentially virulent strains 
(LUQUE et al. 2010). As described above, infection may develop after horizontal or vertical transfer of 
the pathogen from pig to pig or may be transmitted through fomites such as dust and faeces or live 
vectors including flies (ELLIOTT et al. 1966, CLIFTON-HADLEY and ENRIGHT 1984, ENRIGHT et al. 
1987, AMASS et al. 1995). Stress factors like overcrowding, bad ventilation and mixing of animals 
with an age gap of more than two weeks are considered predisposing risk factors for S. suis disease 
(STAATS et al. 1997, GOTTSCHALK 2012). PRRSV infection leads to higher susceptibility of piglets to 
S. suis disease (GALINA et al. 1994). The same applies to swine influenza virus (SIV) or Bordetella (B.) 
bronchiseptica infections (VECHT et al. 1989, LIN et al. 2015). In severe cases, S. suis infection leads to 
peracute death which may occur without any particular clinical signs (WINDSOR and ELLIOTT 1975, 
CLIFTON-HADLEY and ALEXANDER 1988). Otherwise, the early onset of disease is associated with 
fever (up to 42.5°C), possibly accompanied by bacteraemia which is considered an important step in 
S. suis pathogenesis (CLIFTON-HADLEY et al. 1985). The presentation of clinical signs in case of acute 
disease depends on the affected sites and includes CNS dysfunction, such as convulsions or 
opisthotonus, lameness or recumbency and less specifically inappetence and depression (CLIFTON-
HADLEY and ALEXANDER 1988). This can develop into death, chronic disease or a healthy carrier 
status (STAATS et al. 1997). Histopathological investigation of affected organs is mainly characterized 
by fibrinosuppurative lesions (WILLIAMS A. E. and BLAKEMORE W. F. 1990, REAMS et al. 1994, 
MADSEN et al. 2002). 
Human cases of S. suis infection have increased in the past two decades, with most cases described 
in Asian countries (WERTHEIM et al. 2009, LUN et al. 2007, GOYETTE-DESJARDINS et al. 2014) 
accounting for 83.6% of human cases worldwide, whereas 8.5% have been reported from Europe and 
only very few cases from North America and other parts of the world. Most infections are caused by 
serotype 2 of ST 1 (GOYETTE-DESJARDINS et al. 2014). Patients present themselves mainly with 
symptoms of meningitis, such as neck stiffness, severe headache and confusion. Sometimes sepsis 
and less often arthritis, endophthalmitis, endocarditis and pneumonia may be diagnosed. S. suis is 
the main cause of bacterial meningitis in adults in Vietnam (MAI et al. 2008), the second most 
common cause of streptococcal meningitis in Thailand (SUANKRATAY et al. 2004, WIWANITKIT 2017) 
and the third in Hong Kong (HUI et al. 2005). A further very severe form of disease is STSS which is 
associated with petechiae, erythematous rash and multi-organ failure. Numerous cases of STSS 
occurred in the major outbreak in Sichuan Province, China, in 2005 (TANG et al. 2006, YE et al. 2006). 
The main long-term consequence is hearing loss. People with contact to swine or raw pork products, 
be it due to their profession or cultural background and diet, are at a higher risk of getting infected 
by S. suis. As the port of entry, skin lesions and the gastrointestinal route are discussed (ARENDS and 





2.1.6 Association of MRP, SLY and EF with virulence 
In the past, it has been attempted to associate S. suis virulence in pigs with a certain geno- and 
phenotype with ambiguous results. One focus lay on the proteins MRP, EF and SLY. Since MRP+ 
serotype 2 strains in the Netherlands especially in combination with EF were shown to be more 
virulent than MRP- and EF- strains (VECHT et al. 1989, VECHT et al. 1992), many following studies 
focused on MRP and EF as important virulence factors of S. suis serotype 2. The MRP+ EF+ phenotype 
is also present in other serotypes such as 1, 1/2 and 14. However, serotype 9 strains generally do not 
express EF but often MRP in a larger size variant designated MRP* (LUQUE et al. 1998, WISSELINK et 
al. 2000, ALLGAIER et al. 2001). Serotype 7 isolates were also never shown to express EF and seem to 
only express MRP* or a truncated MRP of approximately 76kDa, thus at least EF might not be 
important for serotype 7 virulence (WISSELINK et al. 2000, FITTIPALDI et al. 2009, UNTERWEGER et 
al. 2014). The mrp gene encoding MRP was shown to be very variable in mainly 
pneumonia-associated serotype 7 strains (SILVA et al. 2006). 
The hemolysin SLY is considered another important virulence (-associated) factor especially for 
European S. suis isolates and is often investigated in virulence studies (JACOBS et al. 1994). In Asia, 
the S. suis epf+ mrp+ sly+ genotype of serotype 2 isolates is frequently detected and mostly associated 
with expression of the respective proteins (MAI et al. 2008, KERDSIN et al. 2011, YE et al. 2006). On 
the other hand, North American isolates are mainly of a different geno-/ phenotype. In Canada, 
hardly any strain isolated from diseased pigs expresses MRP, EF or SLY, neither in combination nor 
alone (GOTTSCHALK et al. 1998) and prevalence of MRP+EF+ strains from the USA is also lower than 
described in some European countries. However, production of MRP or SLY alone is frequently 
detected in strains of several serotypes (GALINA et al. 1996, FITTIPALDI et al. 2009).  
Altogether, MRP, EF and SLY are proteins strongly associated with virulence of European and Asian 
strains especially of serotype 2 whereas North American strains rarely show this phenotype and are 
supposedly less virulent than the Eurasian strains (GOTTSCHALK and SEGURA 2000, GOTTSCHALK et 
al. 2007).  
 
2.1.7 Relation of S. suis disease and serotype 
Serotype 2 is frequently isolated from human and swine cases of S. suis disease and is thus 
considered the most virulent serotype (GOTTSCHALK et al. 2007) though under experimental 
conditions serotype 1 has proven more virulent (VECHT et al. 1996, SMITH et al. 1997). An American 
retrospective study of field isolates of serotypes 1-8 and 1/2 revealed no significant connection 
between serotypes and clinical signs of disease (REAMS et al. 1994). Nevertheless, serotype 1 
seemed to be more present in cases with neurological signs and accordingly fibrinosuppurative 
meningitis whereas the other investigated serotypes were rather connected to respiratory disease. In 
those cases it was however questionable whether S. suis was the primary cause of disease (REAMS et 
al. 1994). For serotype 9 strains isolated in the USA, no pathotype-association could be proven. On 
the other hand serotype 7 was associated with a pathogenic pathotype, defined as being the primary 
cause of meningitis, arthritis, epicarditis and septicaemia (ESTRADA et al. 2019). Danish serotype 7 




Eleven years later the same serotype was mainly related to pneumonia and pleuritis closely followed 
by septicaemia which rarely occurred in other serotypes. Serotype 2 was also mainly associated with 
pneumonia and pleuritis followed by meningitis (AARESTRUP et al. 1998). Serotype 9 proved highly 
diverse in a Chinese study regarding virulence and genetics. It was impossible to associate the 
genotype with virulence in general (not referring to specific pathologies) in a mouse model. None of 
the investigated strains carried the sly or epf gene and only 6.6% of the strains were positive for the 
mrp gene (DONG et al. 2017). High heterogeneity in serotype 9 isolates was also observed in 
Canadian S. suis strains which contrasts with those of Spanish or Dutch origin (SCHULTSZ et al. 2012, 
ZHENG et al. 2018). Interestingly, statistically significant association of S. suis serotype 9 with nervous 
disorders and a high prevalence of endocarditis was noted (TARRADAS et al. 2004). Some authors 
rather focused on association of serotype and three pathotype categories than trying to associate 
distinct pathologies with a certain serotype. Categories basically distinguish invasive disease, 
including meningitis and arthritis from opportunistic infection, including cases of pneumonia and 
finally carrier status of healthy pigs. Only few serotypes including 1, 2, 1/2, 7, 9 and 14 are associated 
with the invasive pathotype, whereas more serotypes appear in the opportunistic pathotype and the 
greatest variety of serotypes (and also most untypable isolates) are found in carrier pigs (ALLGAIER et 
al. 2001, ESTRADA et al. 2019, PRÜFER et al. 2019).  
In summary, association of serotype with a specific pathology or pathotype has been described but 
cannot be generalized. ESTRADA et al. (2019) proposed the ST to be the better predictor of a certain 
pathotype. Their data showed association of several STs, e.g. ST1, ST13, ST25, ST28, ST29 or ST94 
with a pathogenic pathotype. Other STs like ST969 or ST750 were associated with a possibly 
opportunistic or commensal pathotype, respectively.  
 
2.2 Vaccination strategies to prevent S. suis disease 
2.2.1 Bacterins and autogenous vaccines 
No commercial vaccine is available in Europe for protection against disease caused by various S. suis 
pathotypes (SEGURA 2015). Until today, pig farmers in Central Europe can only fall back on 
autogenous vaccines applied to either sows ante partum or to piglets. For autogenous vaccine 
production virulent isolates obtained from usually sterile tissues are used (HAESEBROUCK et al. 2004, 
UNTERWEGER et al. 2014). As described above, serotypes 2, 9 and 7 are of special interest in Europe. 
It was shown that autogenous serotype 2 vaccines can elicit protection against homologous 
challenge and protection correlates with the induction of opsonizing antibodies (BAUMS et al. 2009, 
WISSELINK et al. 2002). On the other hand, the protective efficacy against heterologous experimental 
challenge after serotype 2 bacterin immunization was unsatisfactory (BAUMS et al. 2009). Results of 
a field study regarding an autogenous serotype 7 vaccine did not reveal clear protection against 
disease, at least not for suckling piglet vaccination (UNTERWEGER et al. 2014). Neither protection 
against morbidity following serotype 9 S. suis infection (BÜTTNER et al. 2012) nor prevention from 
transmission or colonization after vaccination with a serotype 9 bacterin was achieved (DEKKER et al. 
2011). Accordingly, this serotype remains challenging regarding prophylaxis of S. suis disease. Most 
published work focuses on piglet vaccination (see Table 1). Nevertheless, depending on the onset of 




successfully been evaluated in experimental settings (HSUEH et al. 2017, BAUMS et al. 2010, AMASS 
et al. 2000). Additionally, immunization of sows with a serotype 2 bacterin in combination with 
antibiotic treatment was described as a method to produce S. suis serotype 2 free piglets (SWILDENS 
et al. 2007). Passive maternal immunity induced by a serotype 14 bacterin was shown to only 
partially protect piglets against clinical signs of disease (AMASS et al. 2000), whereas a serotype 2 
autogenous bacterin applied to periparturient sows was more successful and protected piglets until 
six weeks of age. Immunization of suckling piglets from either vaccinated or non-vaccinated sows had 
no protective effect (BAUMS et al. 2010). As interference of maternal and piglet immunity poses a 
problem (BAUMS et al. 2010, HSUEH et al. 2017, HAESEBROUCK et al. 2004), HAESEBROUCK et al. 
(2004) advise not to immunize piglets before an age of 3 to 4 weeks. The importance of an adequate 
vaccination scheme is highlighted. This should include prime-boost vaccination with an interval of at 
least two weeks and a further gap of two weeks between boost and the time of risk. In addition to 
the vaccination scheme, adjuvants also influence the protective efficacy of a vaccine (HAESEBROUCK 
et al. 2004). Regarding whole-cell vaccines, water-in-oil adjuvants for example are superior to 
aluminum hydroxide, albeit leading to stronger reactions at the vaccination site (WISSELINK et al. 
2001).  
In conclusion, as recently evaluated in a field study (HOPKINS et al. 2019), the use of autogenous 
vaccines is generally reasonable in serotype 2 affected herds. Both sow and weaning piglet 
vaccination may be successful. Regarding other serotypes, the effect of immunization with an 
(autogenous) bacterin is questionable. The vaccination scheme and adjuvant used are important 
influencing factors for the efficacy of a bacterin. Finally, an important disadvantage of autogenous 
vaccines is the lack of information on vaccine safety and efficacy data, as in contrast to commercially 













2.2.2 Subunit vaccines 
Since, apart from serotype 2, (autogenous) bacterin vaccines do not provide the desired success 
regarding protection against homologous and especially heterologous S. suis infection, research in 
recent years has increasingly focused on subunit vaccines (SEGURA 2015). Most studies concentrated 
on S. suis serotype 2. Although some subunit vaccines were shown to elicit protection against S. suis 
serotype 2 infection, cross-protection against heterologous challenge was rarely analysed (SEGURA 
2015). In fact, established experimental infection models are limited to only a few serotypes (see 
section 2.4). Following the 2005 outbreak of S. suis disease in humans in China, S. suis research has 
increased and knowledge on factors involved in pathogenesis has improved (FITTIPALDI et al. 2012). 
Whole genome-sequencing has contributed to this, too. Many of the virulence (-associated) factors 
were proposed as potential (cross-protective) vaccine candidates including long known factors such 
as SLY, MRP or EF. Combination of MRP and EF provided good protection against homologous and 
heterologous serotype 2 challenge but the degree of protection depended on the adjuvant used 
(WISSELINK et al. 2001). SLY vaccination partially protected pigs in a homologous challenge model 
(JACOBS et al. 1996). However, these proteins are not conserved between different serotypes or 
even strains of the same serotype (see also 2.1.6) (KING et al. 2001, VECHT et al. 1991). Another 
antigen of constant interest is the non-immunogenic and T cell independent CPS. Only low antibody 
titres against CPS could be obtained by immunizing pigs repeatedly with purified CPS alone (ELLIOTT 
et al. 1980) or by using an adjuvanted bacterin (BAUMS et al. 2009). To investigate the Ig pattern 
directed against CPS, pigs were infected with a virulent serotype 2 strain. No IgG1 or IgG2, but only a 
weak α-CPS IgM response was detected five weeks after challenge (CALZAS et al. 2015). In order to 
overcome the poor immunogenic and T cell independent nature of the CPS, vaccination of mice and 
pigs with tetanus-toxoid conjugated CPS was conducted and resulted in protection. As the CPS is the 
basis for serotyping, this approach may lead to serotype-specific but strain and sequence type 
independent protection (GOYETTE-DESJARDINS et al. 2016). So far, only two single protein antigens 
were able to induce full protection against mortality caused by homologous S. suis infection in swine, 
namely the 38-kDa protein and the recombinant (r) IdeSsuis (OKWUMABUA and CHINNAPAPAKKAGARI 
2005, SEELE et al. 2015b).  
Given that opsonophagocytosis primarily mediates host protection against S. suis infection (CHABOT-
ROY et al. 2006, SEGURA 2015), as mentioned above, the use of the right adjuvant and possibly 
parenteral intramuscular (i.m.) application plays an important role (BROCKMEIER et al. 2018). For 
surface antigen one (SAO) it was demonstrated, that better protection was conveyed when 
adjuvanted with the saponin based Quil A® than with the water in oil adjuvant Emulsigen-Plus (LI et 
al. 2006, LI et al. 2007). The authors discussed the function of different IgG subtypes and proposed 
that IgG2 and a related T-helper(h)1-like immune response enhances opsonophagocytosis, which 
may be influenced by the adjuvant used (LI et al. 2006). However, biochemical methods to separate 
the different porcine IgG subclasses are so far missing, thus the distinction of IgG1 and IgG2 is 
questionable (BUTLER et al. 2009b, BAUMS et al. 2009).  
In an in vitro model using porcine bone marrow dendritic cells, the capacity of adjuvants to stimulate 
either a Th1 or Th2 immune response was evaluated. It revealed that Quil A® promotes a Th1 
response, supporting the results obtained by LI et al. (2007), whereas water-in-oil adjuvants such as 




immune response was also modulated by the nature of the antigen. Importantly, interspecies 
differences between swine, humans and mice exist regarding the impact of adjuvants, antigens and 
the subsequent immune response, thus transferability of results is problematic (MARTELET et al. 
2017). When evaluating vaccine efficacies, the pig model should be favoured (Table 2), as observed 
protection is generally lower in the natural host compared to the mouse model (SEGURA 2015). 
Purified SLY for example conferred 100% protection in mice whereas piglets were not fully protected 
against morbidity (JACOBS et al. 1996, JACOBS et al. 1994). The same result was obtained for the 
recombinant secreted metalloendopeptidase of S. suis, rSsPepO (LI et al. 2011).  
Taken together, recent work on subunit vaccines has mainly focused on surface-associated antigens 
(Table 2) with some promising results. However, achieving heterologous protection still poses a 

















2.3 Selected aspects of the immune system with a focus on swine 
2.3.1 Basics of the innate and early adaptive porcine humoral immune system 
The pig has a diffuse placenta epitheliochorialis (MACDONALD and BOSMA 1985) which means that 
the intake of colostrum is obligatory and the passive immunity of the newborn piglet is almost 
completely dependent on the Ig content in colostrum and milk (BOURNE et al. 1978, BOURNE et al. 
1975). After colostrum uptake serum Ig levels in newborn piglets reach their maximum as soon as 24 
hours (h) post natum. The levels then decrease at different paces and reach their minimum with IgM 
being the first to decline at 8-14 days (d), followed by IgA at 17-22d and IgG at 36-40d. Accordingly, 
the levels rise again with the growing immune system of the piglet: first IgM, then IgA and finally IgG 
are produced (BOURNE 1973, KLOBASA et al. 1981). The beginning of antibody production depends 
on the intake of colostrum. In piglets deprived of colostrum, IgM production starts directly after 
birth, followed by IgG and IgA during the first week of life (KLOBASA et al. 1981). Apart from Igs 
transferred from sow to piglets, so called natural antibodies form the first line of defence and target 
antigens to lymphoid organs. These antibodies are polyreactive and mainly represented by IgM 
(OCHSENBEIN and ZINKERNAGEL 2000, OCHSENBEIN et al. 1999). The mature porcine humoral 
immune response consists of IgM, IgA, IgE and IgG antibodies. For IgG, 6 subclasses are described 
which, except for IgG3, have two allotypes (a and b) each. To date, it is not possible to separate these 
subclasses biochemically (BUTLER et al. 2009a, BUTLER et al. 2009b).  
 
2.3.2 The importance of cellular immunity in protection against streptococcal disease 
For protection against some pathogens like HIV (human immunodeficiency virus), Leishmania and 
Mycobacterium tuberculosis, it has been shown that the T cell response plays a key role also with 
regard to vaccination (SEDER et al. 2008). Cellular immunity is of substantial importance in protection 
against the S. suis related bacterium S. pneumoniae. Nasopharyngeal colonization with 
S. pneumoniae elicits a humoral as well as a cellular immune response sufficient to protect from 
subsequent infection. It is therefore considered an incident of immunization leading to naturally 
acquired immunity. However, as recently reviewed, the critical elements of host resistance are 
distinct depending on the affected sites (RAMOS-SEVILLANO et al. 2019). Regarding colonization of 
the nasopharynx, cluster of differentiation (CD) 4+ T cells were shown to be critical for host resistance 
and their induction and recall is antigen-specific (TRZCINSKI et al. 2008). On the other hand, 
protection from lung infection due to S. pneumoniae was shown to be dependent on both, humoral 
and cellular immunity, as depletion of either CD4+ T cells or antibodies each resulted in lack of 
protection. The authors could further show that depletion of IL-17 also leads to loss of protection. 
Thus, IL-17 producing CD4+ cells play a key role in protection against pneumococcal pneumonia 
(WILSON et al. 2015). Finally, protection from invasive disease caused by S. pneumoniae rather 
depends on antibodies mediating phagocytosis than cellular immunity as antibody deficient mice 
were not protected from bacteraemia whereas CD4 cell depletion had no effect on susceptibility 
(COHEN et al. 2011).  
Little is known about the relevance and characteristics of T cell mediated responses to S. suis, 




mediated by opsonophagocytosis which is associated with a Th1 immune response (SEGURA 2015). 
However, Th1 and Th2 cells are poorly investigated in pigs (GERNER et al. 2009). Recently it was 
shown for the first time that CD4+ T cells are part of the Th1 response to S. suis infection in mice and 
that CPS interferes with activation but not proliferation of these cells. Results suggested though that 
the role of CD4+ T cells in controlling S. suis infection might be limited (LECOURS et al. 2016). Due to 
the lack of reagents and methods, knowledge on porcine cellular immunity is even scarcer. 
Nevertheless, recently CD154 was established as a marker for antigen-specific T cells in swine 
enabling the detection of specific Th cells in host-pathogen-interaction and vaccination (EBNER et al. 
2017). 
 
2.3.3 IgM and its distinctive features in pigs 
In general, IgM belongs to the polymeric Ig class. Secretory IgM, the fraction mainly present in 
normal serum, forms pentamers and occasionally hexamers (KLIMOVICH 2011). Accordingly, it is the 
largest Ig with a molecular weight of ~900kDa. The pentamer consists of five 180kDa monomers 
linked by disulphide bonds and finally connected by the so-called joining (J) chain to form a circle. 
The monomers themselves are built by two light κ or λ chains and two heavy μ chains. Different from 
the heavy γ chains of IgG, μ chains possess a 4th constant domain and have no hinge region (TIZARD 
2018). For interaction with different cells, three IgM receptors have been described. The polymeric Ig 
receptor (pIgR), which also recognizes IgA molecules, is expressed on mucous epithelium and ducts 
of excretory glands and transfers the Ig to the apical side of the respective cells (KAETZEL 2005, 
KLIMOVICH 2011). The Fcα/μR is expressed in all lymphoid tissues and several organs of the non-
hematopoietic system. Furthermore, most B lymphocytes and macrophages carry this receptor whilst 
it cannot be detected on T cells, granulocytes and natural killer (NK) cells. IgA is also able to bind to 
this receptor (SHIBUYA et al. 2000, SAKAMOTO et al. 2001, KLIMOVICH 2011). Only pentameric IgM 
can bind to both aforementioned receptors (BRANDTZAEG and PRYDZ 1984, KAETZEL 2005, 
KLIMOVICH 2011). The third receptor, namely FcµR, is a 60kDa transmembrane protein binding 
specifically IgM. In humans, expression is limited to B and T cells, in mice to B cells (KUBAGAWA et al. 
2009, SHIMA et al. 2010). However, in swine only the pIgR has been detected on protein level 
(TREVISI et al. 2013). 
Due to 10 antigen-binding sites, the IgM pentamer has a high avidity which depends on the ligand 
size but it binds antigens only with a low affinity (MÄKELÄ et al. 1970, EDBERG et al. 1972). An 
important component of IgM defence reactions is agglutination, which due to the pentameric 
structure is 100 to 10,000x higher than that of IgG (KLIMOVICH 2011). The IgM structure and the 
presence of a C1q binding motif on the constant domain 3 of the heavy chain allow IgM to activate 
complement more efficiently than IgG. For this, a reorganization of the IgM molecule conformation is 
necessary to expose C1q binding sites (FEINSTEIN et al. 1986, CZAJKOWSKY and SHAO 2009, 
KLIMOVICH 2011, MERLE et al. 2015, MURPHY and WEAVER 2018). The IgM monomer is not able to 
activate complement but it fulfils another important role: monomeric IgM is part of the B cell 
receptor (BCR) representing the antigen binding component. In swine, IgM is the only BCR as they 




Comparing antigen free (AGF), germfree (GF) and specific pathogen free (SPF) mice, it was shown 
that a stable IgM level is present in adult mice and that the IgM reactivities to known and unknown 
antigens show similar patterns independent of the infectious background, thus indicating cross-
reactivity. Endogenous stimulation through autoantigens and a genetic component were discussed as 
an explanation for the stable IgM level (HAURY et al. 1997). HAURY et al. (1997) described natural 
antibodies in their study, albeit not calling them that. As mentioned above, these antibodies form the 
first line of defence against unknown antigens (BOES et al. 1998b, OCHSENBEIN and ZINKERNAGEL 
2000). As IgM represents the majority of natural antibodies, it plays a key role in the innate immune 
response. The cells producing these polyreactive IgMs are mainly the self-replenishing CD5+ B1a cells 
from the peritoneal and pleural cavities (HAYAKAWA et al. 1985, MARCOS et al. 1989, OCHSENBEIN 
and ZINKERNAGEL 2000). In a mouse S. pneumoniae infection model the roles of B1 cells and the 
influence of CD19 expression were further investigated. B1a cells were shown to mainly produce 
natural antibodies, whereas B1b cells characterize the adaptive immune response to T cell 
independent antigens such as capsular polysaccharides. Thus, through both cell subsets there is a link 
between the innate and adaptive humoral immune response (HAAS et al. 2005). Apart from being 
the major natural antibody, IgM is also the first antibody to be produced in response to most 
pathogens (TIZARD 2018) and the first to be produced in the developing immune system of the piglet 
(see 2.3.1). It represents an important link between the innate and adaptive humoral immune 
response and is probably involved in the feedback mechanism regarding B1 cell development and 
sustainment. Mice deficient in secreted IgM showed increased numbers of peritoneal B1 cells and an 
impaired IgG adaptive immune response (BOES et al. 1998a).  
 
2.3.4 Characteristics of the immunoglobulin M-degrading enzyme of S. suis (IdeSsuis) 
Several mechanisms enabling S. suis to invade the host and to cause disease have already been 
described (see 2.1.4). Immune evasion is one of them and IdeSsuis herein plays a key role (SEELE et al. 
2015a, RUNGELRATH et al. 2018). IdeSsuis is similar to the 38kDa IgG-cleaving endopeptidase of 
S. pyogenes but cleaves specifically porcine IgM. Even IgM of closely related species such as the 
warthog is not degraded by this protease (SEELE et al. 2013). Thus, IdeSsuis is the first factor to explain 
the adaptation of S. suis to its main host, the pig. Expression and secretion of the 124kDa protease 
IdeSsuis was detected in all strains investigated so far, including strains of clonal complexes 1, 27 and 
16 and four serotypes (2, 7, 9 and 5). However, Western blot analysis revealed differences in size 
(SEELE et al. 2013). The putative C1q binding motif, essential for activation of the classical 
complement pathway, is located on the constant (C) domain 3 of the IgM heavy chain (KLIMOVICH 
2011). It could be shown, that IdeSsuis cleaves the heavy chain between C2 and C3 resulting in cleaving 
products of 32kDa and 41kDa and thus a C3-C4 pentamer of which the stability and putative 
functions have to be further evaluated (SEELE et al. 2015a). Investigations regarding the advantage 
for S. suis in carrying ideSsuis in host pathogen interaction revealed that an ideSsuis deficient mutant of 
serotype 2 strain 10 (10∆ideSsuis) is impaired in virulence at least in infection of piglets with high IgM 
titres (SEELE et al. 2015a). In different ex vivo assays it could be shown that attenuation of 10∆ideSsuis 
was complement-dependent. IdeSsuis is a cysteine protease that is important for survival in porcine 
blood especially in animals with high IgM titres as it cleaves IgM and thus detaches it from bacterial 




and different ideSsuis mutant strains revealed that IgM cleavage by IdeSsuis is not essential for the onset 
of meningitis caused by S. suis serotype 2 (SEELE et al. 2015a, RUNGELRATH et al. 2018). In a 
vaccination approach, IdeSsuis was shown to be a highly protective antigen against serotype 2 
challenge in 8-week-old piglets. Astonishingly, protection was not only elicited in bacterin-primed 
piglets with high IgM titres but also in piglets prime and boost vaccinated with rIdeSsuis alone (SEELE et 
al. 2015b). 
 
2.4 Experimental S. suis infections 
Since dissenting results have been obtained in different virulence and vaccine studies, the lack of 
standardization of animal experiments has been criticized (AUGER et al. 2017, FITTIPALDI et al. 2012, 
SEGURA et al. 2017). This passage shall highlight challenges in conducting experimental infections as 
described in literature. The choice of animal model is the first step. As mentioned before, mice are 
frequently used because characteristics of disease can be reproduced in this species. Due to their low 
variability and moderate cost compared to pigs, this model is often preferred (SEGURA et al. 2017). 
However, since the pig is the main host of S. suis the focus should be on this species (Table 3). Most 
information regarding experimental challenge models is available for serotype 2, of which several 
strains have been used. Serotype 9 infection has also been conducted by some research groups 
(BAUMS et al. 2009, BEINEKE et al. 2008, VECHT et al. 1996, DEKKER et al. 2011) and sporadically 
serotypes 1, 7 and 14 have been used (VECHT et al. 1996, AMASS et al. 2000, BOETNER et al. 1987). 
When establishing an infection scheme, differences in susceptibility regarding certain age groups of 
pigs should be considered. Natural infection with S. suis serotypes 1 and 7 is associated with younger 
pigs of less than three weeks of age, whereas serotype 2 affects older piglets of at average 6 weeks 
or older (REAMS et al. 1993, BOETNER et al. 1987, AARESTRUP et al. 1998, ELLIOTT et al. 1980). A 
Dutch study reported divergent results, seeing no difference in age susceptibility between serotypes 
2, 7 and 9 but also associated serotype 1 with young piglets (3 weeks) (WISSELINK et al. 2000). 
Whereas in mice the intraperitoneal (i.p.) route of infection is often used, in pigs intravenous (i.v.) 
challenge is favoured (SEGURA et al. 2017). However, several different application methods are 
described including the intracisternal (i.c.) route used specifically in order to understand the entrance 
of S. suis into the CNS (WILLIAMS A. E. and BLAKEMORE W. F. 1990). Intranasal bacterial inoculation 
takes the natural route of infection into account and thus seems an appropriate model. It is, 
however, often ineffective without predisposition through either an irritant, such as acetic acid (AA) 
or other pathogens like PRRSV or B. bronchiseptica (GALINA et al. 1994, PALLARÉS et al. 2003, VECHT 
et al. 1989). Intranasal infection has been successfully performed with serotypes 1 and 2 whereas for 
serotype 9 mortality and morbidity have only been induced after i.v. inoculation (BEINEKE et al. 2008, 
VECHT et al. 1996, DE GREEFF et al. 2011). However, using another challenge strain, DEKKER et al. 
(2011) did induce low mortality and morbidity infecting caesarean-derived colostrum-deprived 
(CDCD) piglets intranasally with serotype 9 even without predisposition (DEKKER et al. 2011). 
Taken together, the aforementioned literature demonstrates that new challenge models are needed 
and research in vaccination against S. suis disease has so far not lead to satisfactory results. The aim 




establish infection models with regard to future studies, in particular vaccination studies, and to 


























3.1 Streptococcus suis cps7: an emerging virulent sequence type (ST29) shows a distinct, 
IgM-determined pattern of bacterial survival in blood of piglets during the early 
adaptive immune response after weaning 
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The present research article ‘Streptococcus suis cps7: an emerging virulent sequence type (ST29) 
shows a distinct, IgM-determined pattern of bacterial survival in blood of piglets during the early 
adaptive immune response after weaning’ was prepared with the following contributions of the 
authors: I conducted all the genotyping of the S. suis strains, including PCR and MLST. Bacteria were 
grown and cultured by Anna Seydel and myself. Western blot analyses were performed by me with 
the help of Viktoria Rungelrath. Kerstin Klimke and I carried out enzyme-linked immunosorbent assay 
(ELISA) measurements of IgM and IgG antibodies. Bactericidal assays were conducted by Anna 
Seydel, Viktoria Rungelrath, Kerstin Klimke and myself. Anna Seydel and I took care of the piglets in 
the animal experiment and monitored them every day. Christoph Georg Baums supported us. The 
experimental infection and necropsies were performed by Anna Seydel, Christoph Georg Baums and 
myself. Kristin Szewczyk conducted the histopathological screenings. I designed experiments, 
analysed all data and drafted the manuscript. Christoph Georg Baums conceived the study and 



























































Additional file 1 Sequences of oligonucleotide primers 
Additional file 2 Detection of ideSsuis in different S. suis cps7 strains via PCR 
Additional file 3 IgM titers in the sera of the investigated 6.5 week old cps7 free piglets against cps7 
strain 13-00283-02 are substantially reduced after preabsorption with strain 10cps∆EF 
Additional file 4 Titers of serum IgM antibodies binding to the unencapsulated strain 10cps∆EF 
increase in the five investigated cps7 free piglets from 4.5 to 6.5 weeks of age 
Additional file 5 Scoring of fibrinosuppurative lesions of piglets challenged with S. suis cps7 strain 13-



































Additional file 3 IgM titers in the sera of the investigated 6.5 week old cps7 free piglets against cps7 








Additional file 4 Titers of serum IgM antibodies binding to the unencapsulated strain 10cps∆EF 











3.2 Vaccination with the immunoglobulin M-degrading enzyme of Streptococcus suis, 
IdeSsuis, leads to protection against a highly virulent serotype 9 strain 
 
Karoline Rieckmann, Anna Seydel, Kristin Klose, Gottfried Alber, Christoph G. Baums, Nicole Schütze 




The authors of the article ‘Vaccination with the immunoglobulin M-degrading enzyme of 
Streptococcus suis, IdeSsuis, leads to protection against a highly virulent serotype 9 strain’ contributed 
to this work as follows: I characterized different serotype 9 strains genotypically, including PCR and 
MLST. Bacteria were grown and cultured by Anna Seydel and myself. Anna Seydel and I cared for the 
piglets used in the animal experiment and monitored them every day with support of Christoph G. 
Baums. The experimental infection and final necropsy of the piglets were performed by Anna Seydel, 
Christoph G. Baums and myself. Kristin Klose conducted the histopathological screenings. Bactericidal 
assays were conducted by Anna Seydel and me. Flow cytometry for Th cell analysis was performed by 
Nicole Schütze including statistical analysis of this data. All other data was analysed by me. I was 
majorly involved in the experimental design and drafted the manuscript. Christoph G. Baums and 
Nicole Schütze conceived the study and helped design experiments, supported by Gottfried Alber. All 

















































Fig. S1 Results of the bactericidal assay after the 2nd IdeSsuis-booster-vaccination 
Fig. S2 Body temperature curves of rIdeSsuis-vaccinated piglets after experimental infection with 
S. suis cps9 strain 16085/3b 
Fig. S3 Vaccination-induced adaptive IdeSsuis response is not enhanced by S. suis challenge 
Table S1 Scoring of clinical signs in piglets 
Table S2 Individual clinical scores after cps9 challenge and individual immunological data at different 




































































3.3 Streptococcus suis serotype 9 endocarditis and subsequent severe meningitis in a 
growing pig despite specific bactericidal humoral immunity 
 
Karoline Rieckmann, Kristin Müller, Annette Moter, Christoph G. Baums and Anna Seydel 




In preparation of this case report with the title ‘Streptococcus suis serotype 9 endocarditis and 
subsequent severe meningitis in a growing pig despite specific bactericidal humoral immunity’ Anna 
Seydel and I cared for the piglets used in the experimental challenge experiments and monitored 
them every day. We were supported by Christoph G. Baums. Anna Seydel and I cultured the bacteria. 
The experimental infection and the final necropsies were conducted by Anna Seydel, Christoph G. 
Baums and me. Kristin Szewczyk (née Müller) conducted the histopathological screenings. 
Bactericidal assays were conducted by Anna Seydel and me. Annette Moter performed fluorescence 
in situ hybridization (FISH) of a mitral valve. I analysed the data. I designed experiments and drafted 
the manuscript. Christoph G. Baums and Anna Seydel conceived the study and designed experiments. 





















3.4 A critical review speculating on the protective efficacies of autogenous 
Streptococcus suis bacterins as used in Europe 
 
Karoline Rieckmann, Sophia-Mareike Pendzialek, Thomas Vahlenkamp and Christoph G. Baums 




The authors of this review ‘A critical review speculating on the protective efficacies of autogenous 
Streptococcus suis bacterins as used in Europe’ contributed to this work as follows: Christoph G. 
Baums and I reviewed relevant literature, drafted the manuscript and wrote the major part of it. I 
designed and prepared the Figure with the help of Sophia-Mareike Pendzialek. Sophia-Mareike 
Pendzialek wrote the part on the legal basis for the use of AV. Thomas Vahlenkamp contributed to 





























































S. suis is a highly diverse bacterial species causing major economic losses in swine industry. So far, no 
commercially produced vaccine which confers protection against more than one S. suis serotype is 
available in Europe. Stock farmers and veterinarians can only fall back on autogenous vaccines. 
Challenges regarding the development of a cross-protective vaccine are not only limited to the 
variability of S. suis itself but are also extended to difficulties in comparability and availability of 
experimental models. The aim of this thesis was to get novel insights into distinct and neglected 
S. suis pathotypes important in European countries and to evaluate vaccination against S. suis disease 
using rIdeSsuis as an immunization antigen. I described the emerging S. suis serotype 7 of ST29, 
characterized this distinct pathotype and established a challenge model for future vaccination and 
pathogenesis studies (RIECKMANN et al. 2018). Using a serotype 9 infection model, I showed 
heterologous protection of the antigen IdeSsuis against this important serotype for the first time 
(RIECKMANN et al. 2019). I further highlighted the characteristic of biofilm-formation of serotype 9 
(RIECKMANN et al. 2017). Finally, I critically reviewed protective efficacies of autogenous vaccines 
used in Europe (RIECKMANN et al. 2020). The following general discussion of the articles published as 
part of this thesis shall point out opportunities and challenges faced in S. suis vaccine research and 
the importance of expanding the knowledge on pathotypes other than serotype 2, like serotypes 7 
and 9. 
 
4.1 Assessment of virulence and pathotypes – are results transferable?  
In the past, authors have criticized the inconsistent use of the term ‘virulent’ in connection with 
different S. suis strains. Herein after, S. suis strains isolated from clinical cases of S. suis disease and 
thus with the ability to cause disease with clinical manifestation (in experimental settings or in the 
field) will be referred to as virulent. Further, according to SEGURA et al. (2017) virulence factors will 
be considered only those critical in S. suis pathogenesis as described in section 2.1.4. Factors 
associated with but not essential for virulence like MRP, EF and SLY as mentioned in section 2.1.6, 
will be addressed as ‘virulence-associated’. The term ‘virulence (-associated)’ factors will be used 
when not differentiating critical or only associated virulence factors. 
With certain geographical differences (see 2.1.3), the serotypes most frequently isolated from clinical 
cases of S. suis disease in pigs are serotypes 1 to 9, 14 and 1/2 (WILEMAN et al. 2019). Of these, 
serotype 2 is considered most important worldwide (GOYETTE-DESJARDINS et al. 2014). It may be 
thus stated that serotyping is one option to assess virulence. In this work, serotypes were 
determined using the multiplex (MP) PCR by SILVA et al. (2006). However, there are great differences 
in virulence between isolates of the same serotype as has been extensively shown for S. suis serotype 
2 which harbours highly virulent, moderately virulent and avirulent strains (VECHT et al. 1992). The 
same applies to serotype 9 as recently shown by WILLEMSE et al. (2019), who tested different 
serotype 9 strains in a pig infection model distinguishing virulent from avirulent strains. The authors 
further characterized the cpsK gene as differences in capsule loci were observed which were 
associated with clinical or non-disease associated isolates (WILLEMSE et al. 2019). My own 
observations also revealed differences in virulence of serotype 9 strains. Experimental infection of 




CC94 led to severe clinical manifestations including meningitis and septicaemia (RIECKMANN et al. 
2019). Regarding serotype 7 strains of ST29, ex vivo bactericidal assays of four selected strains 
indicated differences in virulence between these strains. One of the four investigated strains has 
been proven virulent in an animal experiment (RIECKMANN et al. 2018). Assessment of virulence 
through certain factors like MRP, EF and SLY has proven useful for serotype 2 strains outside North 
America (Wisselink et al. 2000; Vecht et al. 1991; Luque et al. 1998; Fittipaldi et al. 2009). However, 
the value of these factors with regard to other serotypes like 7 and 9 is questionable (see 4.3).  
Sequence typing is also used to evaluate virulence as STs reflect phylogenetic relations well. Closely 
related strains e.g. of one ST or CC are supposedly comparable in virulence. Thus, it was suggested, 
that STs are better predictors of pathotypes than serotypes distinguishing between pathogenic, 
possibly commensal and commensal isolates (ESTRADA et al. 2019). My own study revealed an 
association of serotype 7 strains of ST29 with a pathogenic pathotype following the classification of 
ESTRADA et al. (2019) since 14 out of 18 isolates were recovered from invasive sites like brain (n=10), 
joint (n=2) spleen (n=1) and pericardium (n=1) and only three isolates were obtained from lungs 
(RIECKMANN et al. 2018). BOETNER et al. (1987) proposed that serotype 7 is mainly responsible for 
septicaemia and arthritis rather than meningitis. They have investigated field isolates in Denmark 
collected in the range of two years, also describing serotype 7 as a pathogenic pathotype. MLST for 
S. suis was only established in 2002 (KING et al. 2002). Therefore, it remains unknown whether the 
field isolates of BOETNER et al. (1987) all belonged to one ST. However, it is reasonable to 
hypothesize that investigation of isolates belonging to a certain serotype from a particular area 
during a limited period of time as applies to the study of BOETNER et al. (1987) describes one 
emerging clone. In case of the major outbreak of human S. suis cases in China in 2005 for example, it 
was proven that a single clone of ST7 was responsible for the tragedy (YE et al. 2006). My own work 
also describes the emergence of the putative CC29 over a couple of years (RIECKMANN et al. 2018).  
Recently, WILEMAN et al. (2019) introduced a pathotyping scheme using a MP PCR for detection of 
four genes. Two of which were defined as disease-associated, one as non-disease associated and the 
fourth gene served as a species-specific control gene. The authors compared their new pathotyping 
tool to serotyping, sequence typing, determination of virulence-associated genes mrp, epf and sly 
and to minimum core genome sequence typing (MCG). For characterization of strains in this thesis 
the MP PCR as described by SILVA et al. (2006) was used (RIECKMANN et al. 2017, RIECKMANN et al. 
2018, RIECKMANN et al. 2019). The same MP PCR was now evaluated by WILEMAN et al. (2019). In 
contrast to this study, I further determined variants of the gene mrp in several serotype 7 strains 
(RIECKMANN et al. 2018). WILEMAN et al. (2019) concluded that their pathotyping method was 
superior to serotyping and also to determination of the virulence-associated genes mrp, epf and sly 
with significantly better results in positive predictive value and specificity. This new approach may 
solve the problem of unidentified virulent carrier isolates on tonsils and may thus help to assess the 
S. suis status of a herd. However, the new PCR was so far only evaluated using S. suis isolates from 
the UK. Further evaluation in other countries and laboratories should elucidate its true value. 
In conclusion, the different ways assessing virulence/ pathotypes, raise the question whether results 
obtained for one S. suis isolate allow extrapolation to others. Surely, it is not feasible to define 
pathotypes by serotyping, as the literature as well as my own results show great differences between 




factors may help in case of serotype 2 and may allow transmission of results obtained for serotype 2 
strains with the same genetic profile regarding mrp, sly and epf. For serotypes 7 and 9 this remains, 
however, unreliable as these factors are partly not even existent in these serotypes. The more 
detailed strains can be described through either way of assessing virulence/ pathotypes, the easier or 
more probable it may be to extrapolate obtained results from one strain to another. From what is 
known by now, sequence typing seems to represent a very reliable and feasible tool to identify 
closely related isolates. However, there are still differences between strains of one ST indicating that 
this method is not sufficient. Serotyping and characterization of the strains regarding their clinical 
background should also be taken into account and probably combined with sequence typing. 
 
4.2 The importance of new challenge models – characteristic features of serotypes 7 and 9 
The ultimate goal of S. suis vaccine research is the development of a cross-protective vaccine which 
would contribute to a reduction of S. suis disease and the use of antibiotics in swine industry. As 
discussed before, in order to extrapolate results it is essential to know the pathogen. Further, the 
establishment of new challenge models is necessary. 
In the field, autogenous vaccines are frequently used in prevention of S. suis disease. The most 
promising results have so far been obtained for serotype 2 bacterins as has been shown 
experimentally (BAUMS et al. 2010) and recently also suggested by a field study of an autogenous 
serotype 2 vaccine (HOPKINS et al. 2019). S. suis serotype 2 is the best investigated serotype and 
most pathogenesis and vaccine studies have been conducted using strains of this serotype (Tables 1-
3). The success regarding prevention of homologous infection using bacterins of other serotypes like 
7 (UNTERWEGER et al. 2014) and 9 (BÜTTNER et al. 2012) is limited. Moreover, heterologous 
protection is hardly detectable as shown by BAUMS et al. (2009) using a serotype 2 bacterin in 
prevention of S. suis serotype 9 infection. Overall, bacterins may at most be expected to confer 
serotype-, probably ST-specific protection (GOYETTE-DESJARDINS et al. 2016). Furthermore, 
predisposing factors such as infection with PRRSV or the prevalence of more than one serotype 
causing disease in a herd negatively influence the efficacy of a bacterin (RIECKMANN et al. 2020). 
Accordingly, research has focused on subunit vaccines in the past years (SEGURA 2015) which have 
the potential to confer cross-protection but challenge models for serotypes other than serotype 2 
are scarce.  
S. suis serotypes 7 and 9 are often responsible for diseases in pigs worldwide, especially in Europe, 
but only few studies have investigated protective efficacies of bacterins or subunit vaccines against 
these serotypes. S. suis serotype 7 of ST29 displays a distinct pathotype (RIECKMANN et al. 2018). 
Investigation of survival in porcine blood revealed that four selected serotype 7 strains of ST29 
proliferated in blood of weaning piglets and were killed in blood of growers. The high susceptibility of 
weanlings to S. suis serotype 7 is in accordance with the observation of BOETNER et al. (1987) that 
primarily young piglets are affected by S. suis serotype 7. The survival pattern of the investigated 
strains was distinct from a serotype 9 strain which showed the opposite trend (RIECKMANN et al. 
2018, RIECKMANN et al. 2019). Whereas maternal immunity may be responsible for lower survival 
factors of serotype 9 in blood of weaning piglets, it does not seem to affect serotype 7. Interestingly, 




bacterial survival trends, IgM levels against S. suis serotypes 7 and 9 in blood of the same piglets used 
for the bactericidal assays rose almost synchronous from an age of 4.5 weeks to an age of 8.5/ 10.5 
weeks. This demonstrates the high infection pressure due to S. suis faced by piglets during this 
rearing phase. Results of ELISA measurements using sera preabsorbed with a capsule deficient 
mutant of serotype 2 proved that a substantial amount of IgM was directed against other antigens 
than the capsule explaining the rising IgM levels against serotypes which are absent in one of the two 
investigated herds. In the 7th week of life, killing of serotype 7 ST29 strains was IgM-mediated fitting 
rising specific IgM levels. This was demonstrated in bactericidal assays through addition of the IgM 
protease rIdeSsuis which completely cleaved the IgM (RIECKMANN et al. 2018). Accordingly, IgM plays 
an important role in host defence against S. suis serotype 7 strains. For other bacterial pathogens like 
S. pneumoniae and relapsing fever causing Borrelia the importance of IgM in protection is also known 
(HAAS et al. 2005, YOKOTA et al. 1997, ALUGUPALLI et al. 2003). The effect of IdeSsuis decreased after 
the 7th week of life which may be explained by rising levels of opsonizing IgG against S. suis serotype 
7. Serotype 9 on the other hand still proliferated in porcine blood in the 7th week of life suggesting 
that adaptive IgM may play a less important role in host defence against this serotype. 
Intranasal infection of 9 piglets aged ~5 weeks with 1.7-2.8 x 109 CFU of serotype 7 strain #451 did 
not lead to clinical manifestation of S. suis disease. No differences were recorded between the 
infected group and the uninfected control group (n=9/group) (our own unpublished results). As 
described previously, even combined intranasal and intramuscular inoculation with serotype 7 only 
led to mild clinical signs of disease (XU et al. 2010). Thus, it may be concluded that S. suis serotype 7, 
like serotype 9, is less virulent than serotype 2. Based on this knowledge, we conducted an 
intravenous infection with serotype 7 strain 13-00283-02 in a second experiment and successfully 
induced clinical signs of disease and mortality in 5-week-old piglets (RIECKMANN et al. 2018).  
S. suis serotype 9 is the most prevalent serotype in some European countries with a large pig 
industry, such as the Netherlands and Spain (GOYETTE-DESJARDINS et al. 2014). In the Netherlands, 
strains of CC16 are causative for most serotype 9 cases (SCHULTSZ et al. 2012). In earlier 
experimental infections, strain A3286/94 of this CC has been successfully used to induce disease in 
piglets (BAUMS et al. 2009, BÜTTNER et al. 2012). However, in contrast to those previous studies, 
sufficient morbidity and mortality could not be induced using strain A3286/94 in my own experiment 
with the following design: eighteen piglets were prime-boost vaccinated with rIdeSsuis (n=9) or 
placebo-treated (n=9) in the 6th and 8th week of life and challenged intravenously at an age of 64 and 
67 days with strain A3286/94. Apart from fluctuating inner body temperatures in the 7 days following 
infection in piglets of both groups, 17/18 piglets remained clinically unobtrusive (data not shown). 
Only one piglet developed clinical signs 11 days post infection which was published in a case report 
(RIECKMANN et al. 2017). Whether a change in the immune status of the originating herd of the pigs 
or other factors were responsible for this remains unclear. On the one hand, reduced bacterial 
survival of S. suis serotype 2 strain 10 in blood of weaning piglets of this herd was noticeable over the 
past years in accordance with a putative change of the immune status (unpublished data and 
personal communication with Prof. Christoph Baums). On the other hand, S. suis genotypes isolated 
from the tonsils prior to experimental serotype 9 infection were only those known to be present in 
the respective herd and did not belong to serotype 9 (data not shown). Comparable to an earlier 




mitral valve with biofilm formation (discussed below) induced by the same challenge strain which 
subsequently resulted in a fibrinosuppurative leptomeningitis of one piglet (RIECKMANN et al. 2017). 
This complication should be kept in mind by veterinarians confronted with serotype 9 herd problems 
and by scientists planning experimental studies involving S. suis serotype 9. Due to the 
aforementioned reduced morbidity in an experimental infection with strain A3286/94 we chose a 
different serotype 9 challenge strain, namely 16085/3b of ST94, for a further vaccination and 
challenge experiment. Intravenous application of this strain resulted in severe clinical signs of disease 
including meningitis, septicaemia and peracute death in non-vaccinated piglets (RIECKMANN et al. 
2019). Generally, S. suis serotype 9 is considered less virulent than serotype 2 as attempts to induce 
disease by applying the bacteria intranasally, following the natural route of infection, have not been 
successful (VECHT et al. 1996, BEINEKE et al. 2008). However, in case of strain 16085/3b, an 
intranasal challenge might be successful. Despite its high prevalence in Europe, experience with 
S. suis serotype 9 infection models is very limited. Furthermore, a protective antigen against serotype 
9 was not identified previously, although numerous publications reveal protection of specific 
proteins against serotype 2 challenges in mice and pigs (see Table 2 in section 2.2.2 and SEGURA et 
al. (2015)). This drawback in S. suis research is pointed out in the recent publication by WILLEMSE et 
al. (2019): “antigens which generate a protective immune response against serotype 9 challenge, and 
which could be used for vaccine development, have not been described“. 
In summary, by describing distinct pathotypes of S. suis in this thesis, the great diversity of this 
bacterial species was highlighted. In order to obtain the best results, the pig model was chosen as the 
pig is the main host of S. suis. In the past, most studies have focused on S. suis serotype 2. However, 
caution should be taken extrapolating results obtained for one serotype to others. Especially 
regarding vaccination studies, there is an urgent need for challenge models with serotypes other 
than serotype 2 for the investigation of heterologous protection. The animal models established as 
part of my thesis especially with serotype 7 and the detailed vaccination-challenge experiment 
conducted with serotype 9 are therefore steps towards a more comprehensive understanding of 
S. suis pathotypes and the development of a S. suis vaccine with heterologous protection. 
 
4.3 MRP – characteristics and vaccination approaches 
For Eurasian S. suis serotype 2 strains the 136kDa MRP and EF are accepted virulence-associated 
factors in contrast to North American serotype 2 strains as described above. However, MRP 
expression does not only show geographical differences in serotype 2 strains but is also variable in 
other serotypes. Thus, another distinct feature of S. suis serotype 7 strains investigated in my thesis 
is the expression of a small variant of MRP, namely MRPs (<136kDa). WISSELINK et al. (2000) did not 
attribute MRP an important role in virulence of this serotype as they discovered a larger variant of 
MRP, MRP* (>136kDa), in only one out of 23 serotype 7 isolates, including invasive isolates from 
tissues like brain, heart and joints (WISSELINK et al. 2000). However, these investigations were based 
on phenotyping. Genotyping of S. suis serotype 7 isolates revealed a great variance in the mrp gene 
(SILVA et al. 2006) which is in accordance with my own results (RIECKMANN et al. 2018). In contrast 
to this genetic variance, phenotyping of S. suis serotype 7 isolates in my study showed an identical 




mainly in the culture supernatant regardless of the mrp gene variant (RIECKMANN et al. 2018). 
Subsequent sequencing of the mrp genes (different variants) of four selected S. suis serotype 7 
strains revealed a premature stop codon as has been described previously for other serotype 7 
strains (FITTIPALDI et al. 2009). This explains the weak bands observed in Western blot analysis of the 
protoplast supernatants as an LPXTG motif through which MRP is usually bound to the bacterial 
surface (SMITH et al. 1992) does not exist in the short MRP variant (RIECKMANN et al. 2018). For 
S. suis serotype 2 the function of MRP has recently been described as fibrinogen-binding, which was 
shown to add to the antiphagocytic ability of S. suis and to promote the development of meningitis 
caused by this serotype (PIAN et al. 2015, WANG et al. 2015). Due to the missing LPXTG motif of MRP 
in the investigated S. suis serotype 7 strains the fibrinogen-binding function is questionable. Instead, 
it is conceivable that serotype 7 strains use secretion of MRP primarily as an immune evasion 
mechanism.  
MRP is a major immunogen eliciting high levels of specific antibodies (WISSELINK et al. 2001, BAUMS 
et al. 2009). By secretion of MRP S. suis may avoid opsonophagocytic killing through antibodies 
directed against cell wall anchored MRP. This would explain why previous attempts to use MRP as a 
vaccination antigen have failed. Though high levels of antibodies were elicited after vaccination with 
MRP, protection against mortality was not observed, only morbidity was reduced (WISSELINK et al. 
2001). A MAP vaccine containing highly immunogenic proteins like MRP and SAO was further shown 
to elicit specific antibody levels against these proteins. However, they were not opsonizing and thus 
did not protect from homologous or heterologous challenge (BAUMS et al. 2009). This reinforces the 
hypothesis that secretion of MRP serves as an immune evasion mechanism. BAUMS et al. (2009) 
investigated heterologous protection of a serotype 2 (MRP+EF+) bacterin and MAP subunit vaccine 
against a serotype 9 (MRP*) challenge. It remains unclear whether the different MRP variants of the 
bacterin, the subunit vaccine and the heterologous challenge strain contributed to the failure of the 
vaccines.  
In European countries, invasive S. suis serotype 9 strains mainly show a MRP* phenotype (WISSELINK 
et al. 2000, SILVA et al. 2006). The different MRP variants which exist in the S. suis population were 
also seen in this thesis. I investigated serotype 7 strains expressing MRPs (RIECKMANN et al. 2018) 
and used two serotype 9 strains for experimental infection. Of those, strain A3286/94 expresses 
MRP* (RIECKMANN et al. 2017) and strain 16085/3b carries the mrp gene but there are indications 
that it does not secrete MRP at all and only expresses low amounts of cell wall anchored MRP (our 
own unpublished results). Thus, in addition to the results of WISSELINK et al. (2001) and BAUMS et al. 
(2009) the variability and the inconsistent expression of MRP in virulent S. suis strains worldwide 
question the suitability of this protein as a vaccine antigen.  
In summary, the role of MRP as a virulence-associated factor and its function in other serotypes than 
serotype 2 remains unclear. Overall, it seems likely that despite its high immunogenicity this protein 
is unsuitable as a vaccination antigen as especially serotype 7 strains may use secretion of MRP to 
evade the host immune system. Further, results of vaccination studies could not show protection 





4.4 rIdeSsuis - chances and limitations, focusing on vaccination strategies 
In contrast to MRP, the highly specific IgM protease IdeSsuis, identified and characterized by SEELE et 
al. (2013), is not an immunodominant protein. Despite colonization of pigs with S. suis, α-IdeSsuis IgG 
levels are considered negligibly low in non-vaccinated animals which has been shown repeatedly 
(SEELE et al. 2015b, RIECKMANN et al. 2019). Furthermore, there is no boost effect on α-IdeSsuis IgG 
levels or antigen-reactive Th cells through experimental infection with S. suis, again demonstrating 
that IdeSsuis itself is not immunogenic (RIECKMANN et al. 2019). As has been discussed before, this 
may pose a good opportunity to differentiate infected from vaccinated animals (DIVA) in the field. 
Additionally, vaccination of suckling piglets may be an option as interference with maternal immunity 
should not occur (SEELE et al. 2015b). Different from MRP, IdeSsuis expression was proven in all S. suis 
isolates further investigated in this thesis, including different serotype 7 and 9 isolates and was 
detected before in several S. suis isolates suggesting conservation in this bacterial species (SEELE et 
al. 2013). However, there are noticeable variations in the amount of IdeSsuis expression and 
functionality regarding the IgM cleaving activity. Serotype 7 strain V2310/1 for example expresses 
barely detectable amounts of IdeSsuis and even the 30-fold concentrated culture supernatant of this 
strain did not cleave IgM in porcine serum sufficiently enough to allow detection of cleavage 
products through Western blot analysis (RIECKMANN et al. 2018). Thus, it is probable that more 
strains are lacking functional IdeSsuis. Further, variations in size of the enzyme were noted in my study, 
confirming previous results (SEELE et al. 2013). Whether the aforementioned differences observed in 
IdeSsuis expression, functionality and size influence the protective efficacy of an IdeSsuis -based vaccine 
remains to be elucidated in future studies.  
IdeSsuis vaccination was shown to be highly protective against experimental S. suis serotype 2 
infection (SEELE et al. 2015b). In a vaccination and challenge trial using a serotype 9 strain, I 
demonstrated that this antigen further has the potential to confer cross-protection. In this study, 
intravenous application of strain 16085/3b of CC94 led to severe clinical signs of disease in non-
vaccinated animals (RIECKMANN et al. 2019). The majority of placebo-treated piglets died within 32h 
following infection. Ninety per cent mortality in the placebo-treated group contrasted with 0% in the 
rIdeSsuis-vaccinated group. For the first time a S. suis subunit vaccine was shown to protect against 
mortality induced by the important S. suis serotype 9. However, morbidity was observed in both 
groups showing no significant difference. This challenge is regarded to be very hard. Thus, only very 
robust protective immunity may be detectable using this intravenous challenge model. Protection 
from mortality but not morbidity was demonstrated in a previous study using vaccination with a 
serotype 9 bacterin (BÜTTNER et al. 2012). Based on this publication and experiences from the field 
(personal communication with Prof. Dr. Christoph Baums) the protective efficacy of bacterin 
immunization is thought to be limited in prevention of S. suis serotype 9 disease as it may at most 
reduce mortality (RIECKMANN et al. 2020). Whether the protective efficacy of rIdeSsuis immunization 
is also limited to protection against mortality or whether this result is a consequence of the hard 
intravenous challenge remains to be elucidated. In any case, in contrast to rIdeSsuis immunization, 
bacterins may at most confer protection against homologous challenge, meaning bacterins are 
serotype-specific.  
Another challenge regarding vaccination against S. suis is its biofilm forming potential (GRENIER et al. 




serotypes (DAWEI et al. 2012). In a case report I described an endocarditis with biofilm formation on 
the mitral valve in combination with a fibrinosuppurative leptomeningitis after serotype 9 infection 
(RIECKMANN et al. 2017). A piglet, prime-boost vaccinated with rIdeSsuis, was clinically unobtrusive for 
10 days and then developed an acute leptomeningitis on the 11th day post infection despite blood 
bactericidal activity and high IdeSsuis-specific antibody levels. It is known that after bacteria have 
formed biofilms they are highly resistant to antibiotics and the host immune system (STEWART and 
WILLIAM COSTERTON 2001, HØIBY et al. 2011) which includes opsonizing antibodies induced by 
rIdeSsuis vaccination (RIECKMANN et al. 2017). As biofilms are dynamic structures, occasional 
detachment of viable bacteria takes place thus posing a continuous and unpredictable threat (HØIBY 
et al. 2011). Presumably, this is what happened with the piglet described in the case report. A biofilm 
on the mitral valve was proven by the stratified pattern described for biofilms and the detection of 
bacteria in a fibrinous network using fluorescence in situ hybridization (FISH). We suggest that some 
bacteria dissolved from the vegetation and thus reached the meninges and caused a 
fibrinosuppurative leptomeningitis. However, septic embolism was not detected. Interestingly, brain 
lesions have been described in slaughter pigs as putative sequelae of bacterial endocarditis caused by 
S. suis or Erysipelothrix rhusiopathiae (KARSTRUP et al. 2011). In the bacterin immunization study by 
BÜTTNER et al. (2012) three vaccinated piglets were noted which developed an endocarditis. In two 
of them fibrinosuppurative meningitis was also diagnosed. Yet, the endocarditis was not investigated 
further regarding biofilm formation in these three piglets. Endocarditis possibly accompanied by 
biofilm formation is an important complication one should be aware of in case of S. suis infections. 
Whether bacterin or rIdeSsuis vaccination may prevent pathogenesis of endocarditis at early stages, 
should be subject of further investigations. The choice of intravenous application of bacteria as 
conducted by BÜTTNER et al. (2012) and in my own study which bypasses mucosal immunity may be 
one reason for the lack of protection against endocarditis as numerous bacteria might adhere to the 
heart valve simultaneously. Thus, establishing an intranasal infection model with strain 16085/3b for 
example would be desirable.  
Recently, an article was published revealing that only a combination of vaccine antigens directed 
against both planktonic and biofilm-embedded Staphylococcus aureus significantly reduces mortality 
and even eliminates the bacteria in mice and rabbits (HARRO et al. 2019). The authors used a 
quadrivalent vaccine against biofilm-embedded bacteria which has been described before (BRADY et 
al. 2011) and has been shown to only confer sufficient protection when used in combination with 
antibiotic treatment of planktonic bacteria. Accordingly, HARRO et al. (2019) added a planktonically 
upregulated antigen to address planktonic bacteria to the quadrivalent vaccine. Expression and 
regulation of IdeSsuis in biofilm-embedded and planktonic bacteria should be investigated in the 
future. It may be necessary to combine IdeSsuis with other antigens addressing biofilm-embedded 
S. suis to fight this complication. In the control of biofilms caused by Staphylococcus aureus cellular 
immunity, especially IL-17 producing T cells, are assumed to play a role (GIL et al. 2014). 
Furthermore, multifunctional T cells have been shown to be associated with protection against 
different pathogens (DARRAH et al. 2007, SEDER et al. 2008). However, antigen-reactive Th cells have 
so far not been investigated in S. suis vaccine research. In a cooperation with the postdoctoral fellow 
Dr. Nicole Schütze from the Institute of Immunology of the Faculty of Veterinary Medicine, Leipzig 




et al. 2017) were detected for the first time in S. suis vaccine research  . We could show that rIdeSsuis 
vaccination led to production of antigen-reactive Th cells but there was no recall upon infection. 
Accordingly, IdeSsuis is probably not an immunodominant T cell antigen. Anyhow, correlation of IgG 
antibody levels and Th cells indicate a supporting role of the cellular component for the humoral 
immune response to IdeSsuis.  
All in all, IdeSsuis has been proven to be a conserved enzyme in S. suis albeit differences in size, 
expression and functionality between strains. Due to its low immunogenicity and its conservation, 
this protein is clearly advantageous over the use of MRP-based vaccines or bacterins. In contrast to 
MRP-based vaccines and bacterins, rIdeSsuis immunization allows for DIVA and may allow suckling 
piglet vaccination. Finally, and most importantly, for the first time protection against serotype 9 using 
a recombinant antigen was demonstrated thus proving cross-protection of this antigen not only 
covering strains of different serotypes but also of different STs and CCs, which may not be achieved 
using bacterin immunization. These results are highly encouraging regarding the development of a 
cross-protective vaccine for the prevention of S. suis disease.  
 
4.5 Conclusions 
In this thesis two important S. suis pathotypes were characterized: S. suis serotype 7 strains of ST 29 
and a highly virulent serotype 9 strain of ST94. Especially strains of serotype 7 constitute a distinct 
pathotype and adaptive IgM plays an important role in its control. The high proliferation of serotype 
7 strains in piglets shortly after weaning is another special feature which is challenging regarding 
prophylaxis against this pathotype and may limit opportunities to vaccination of periparturient sows. 
In a case report focusing on a piglet experimentally infected with serotype 9, biofilm formation on 
the heart valve combined with a chronically-active endocarditis was associated with the 
development of an acute meningitis despite opsonizing antibodies elicited by rIdeSsuis vaccination. 
Thereby, an important complication especially with regard to serotype 9 infection was highlighted. 
Finally, the most important result of my work is the proof of protection against a highly virulent 
serotype 9 strain through rIdeSsuis immunization. This makes IdeSsuis the first cross-protective 
vaccination antigen to confer protection against the two highly prevalent S. suis serotypes 2 and 9. 
This is a very promising result with regard to the development of a vaccine against S. suis which fulfils 
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Einleitung 
Streptococcus (S.) suis verursacht bei Schweinen unter anderem Meningitis, Arthritis, Serositis und 
Endokarditis und ist eine der größten Herausforderungen für die Schweineindustrie. Von 29 
beschriebenen Serotypen sind die Serotypen 2, 7 und 9 unter invasiven Isolaten weltweit besonders 
prävalent, vor allem in Europa. Bis heute gibt es keinen zugelassenen Impfstoff zur Prävention von 
S. suis-Erkrankungen in Europa, daher ist im Feld die Anwendung stallspezifischer Impfstoffe 
verbreitet. Diese bieten jedoch höchstens homologen Schutz und ihre Wirkung kann durch 
prädisponierende Faktoren wie eine Infektion mit dem porcine reproductive and respiratory 
syndrome Virus (PRRSV) beeinträchtigt werden. Daher hat sich die Forschung auf Antigene fokussiert, 
die potentiell heterologen Schutz vermitteln. 
Zielstellung 
Ziele der Studie waren die Charakterisierung vernachlässigter invasiver S. suis Pathotypen der 
wichtigen Serotypen 7 und 9 und die Etablierung neuer Infektionsmodelle im Schwein. Des Weiteren 
sollte die immunogene und protektive Wirkung des Immunoglobulin (Ig) M-degradierenden Enzyms 
von S. suis, IdeSsuis, im Serotyp 9 Infektionsversuch untersucht werden. 
Material und Methoden 
In dieser Arbeit wurden in vitro Versuche und experimentelle Infektionen im Schwein durchgeführt. 
Dazu gehörte die Geno- und Phänotypisierung von 22 S. suis Serotyp 7 Stämmen und vier Serotyp 9 
Stämmen. Die Genotypisierung erfolgte mittels multiplex (MP) Polymerase-Kettenreaktion (PCR), 
einer PCR zur Differenzierung verschiedener Genvarianten des muramidase-release protein (MRP) 
sowie mittels multilocus sequence typing (MLST). Zur Phänotypisierung der S. suis Stämme wurden 
bactericidal assays eingesetzt, die als Bakteriämiemodell fungierten. Auf diese Weise konnten die 
Empfänglichkeit gegenüber S. suis Stämmen sowie deren Virulenz beurteilt werden. Durch Zugabe 
von rekombinantem (r) IdeSsuis wurde die Rolle adaptiven IgMs in der Begrenzung der Bakteriämie 
untersucht. Anhand von Western Blot Analysen erfolgte die Untersuchung der Expression und 
Funktionalität von IdeSsuis sowie die Expression von MRP in S. suis Serotyp 7 Stämmen. Enzyme-linked 
immunosorbent assays (ELISA) kamen zum Einsatz, um die Entwicklung von IgM und IgG Spiegeln in 
Ferkeln im zeitlichen Verlauf und die IgG Spiegel nach rIdeSsuis Immunisierung zu messen. Durch 
rIdeSsuis Immunisierung induzierte Antigen-spezifische T-Helferzellen (Th-Zellen) wurden mithilfe der 
Durchflusszytometrie untersucht. Schließlich erfolgte die Durchführung zweier S. suis Serotyp 7 




Infektionsversuche mit je 18 Ferkeln. Sektionsproben wurden histologisch untersucht. In einem Fall 
wurde eine Endokarditis mittels fluorescence in situ hybridization (FISH) charakterisiert.  
Ergebnisse 
Die meisten untersuchten Serotyp 7 Stämme gehörten dem Sequenztyp (ST) 29 an, einem emerging 
pathotype in Europa. Trotz der engen phylogenetischen Verwandtschaft, war mrp in den Stämmen 
sehr variabel. Phänotypisch bildeten alle Stämme gleichermaßen eine kleine MRP Variante, MRPs. 
Für vier ausgewählte Serotyp 7 Stämme wurde die Expression von IdeSsuis gezeigt, jedoch mit 
Unterschieden in Größe und Funktionalität. Bactericidal assays dieser vier Stämme zeigten starke 
Proliferation im Blut von Absatzferkeln, aber Abtöten im Blut von Läuferschweinen aus zwei Herden 
mit unterschiedlichem S. suis Status. Dieses Überlebensmuster unterschied sich deutlich von dem 
eines Serotyp 9 Stammes. Durch Zugabe von rIdeSsuis, konnte gezeigt werden, dass das Abtöten der 
Serotyp 7 Stämme im Blut von Läuferschweinen des infizierten Bestandes IgM-vermittelt war. 
Unabhängig von der Herkunft entwickelten sich die IgM Spiegel in den Ferkeln im zeitlichen Verlauf 
fast synchron. Schließlich konnte die Virulenz eines Serotyp 7 Stammes in einem intravenösen 
Infektionsversuch mit 5 Ferkeln gezeigt werden. Alle Tiere entwickelten schwere Symptome einer 
S. suis Erkrankung. 
In einem Impf- und Infektionsversuch mit einem hoch virulenten Serotyp 9 Stamm wurde die 
immunogene und protektive Wirkung einer rIdeSsuis Immunisierung untersucht. Neun Ferkel wurden 
mit rIdeSsuis oder einem Placebo prime-boost-boost immunisiert und zwei Wochen später infiziert. 
Neunzig Prozent der Placebotiere entwickelten schwere Symptome einer S. suis Erkrankung und 
starben oder mussten aus Tierschutzgründen euthanasiert werden. Alle geimpften Tiere überlebten 
den Versuch, fielen jedoch mit Fieber und Lahmheiten auf. Es konnte also gezeigt werden, dass eine 
rIdeSsuis Immunisierung vor Mortalität, nicht aber Morbidität durch den Infektionsstamm schützt. Alle 
immunisierten Ferkel serokonvertierten und Antigen-spezifische Th-Zellen wurden nachgewiesen. 
Weder die IgG Antwort noch die Th-Zell Antwort wurde jedoch durch die Infektion verstärkt.  
In einem weiteren Impf- und Infektionsversuch mit einem anderen Serotyp 9 Stamm fiel ein Tier am 
11. Tag nach der Infektion mit Zeichen einer akuten Leptomeningitis auf, nachdem es zuvor klinisch 
völlig unauffällig war. In der Sektion des Tieres wurde eine Endokarditis der Mitralklappe 
diagnostiziert, die mit Biofilm-Bildung assoziiert war, was mithilfe von Histologie und FISH gezeigt 
werden konnte. Zusätzlich wurde eine fibrinopurulente Leptomeningitis diagnostiziert. Das Ferkel 
hatte Antikörper gegen rIdeSsuis und tötete den Infektionsstamm ex vivo im Blut ab.  
Schlussfolgerungen 
In dieser Arbeit habe ich zwei wichtige S. suis Pathotypen charakterisiert: S. suis Serotyp 7 Stämme 
des ST29 und einen hoch virulenten Serotyp 9 Stamm vom ST94. Die Serotyp 7 Stämme stellten einen 
besonderen Pathotypen dar, bei dessen Bekämpfung IgM eine wichtige Rolle spielt. Bei einer Serotyp 
9 Infektion konnten trotz des Abtötens der Bakterien im Blut und opsonisierender Antikörper 
Biofilmbildung und eine folgende akute Leptomeningitis nicht verhindert werden. Letztlich wurde 
Schutz vor einem hoch virulenten Serotyp 9 Stamm durch rIdeSsuis Immunisierung und damit zum 
ersten Mal für ein Antigen Protektion vor den wichtigen Serotypen 2 und 9 aufgezeigt. Dies ist ein 
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Introduction 
Streptococcus (S.) suis causes meningitis, arthritis, serositis and endocarditis and is one of the biggest 
challenges for the swine industry. Of 29 described serotypes, the serotypes 2, 7 and 9 are highly 
prevalent amongst invasive S. suis isolates worldwide, especially in European countries. To date, no 
commercially produced vaccine is available in Europe for prevention of S. suis disease, thus the use of 
autogenous vaccines in the field is common. However, bacterins may at most confer homologous 
protection and their efficacy may be influenced by predisposing factors such as an infection with the 
porcine reproductive and respiratory syndrome virus (PRRSV). Research has therefore focused on 
subunit vaccines with the potential to elicit cross-protection against various serotypes.  
Aim of the study 
The objective of this study was to characterize neglected invasive S. suis pathotypes of the important 
serotypes 7 and 9 and to establish infection models in the main host of S. suis, the pig. A further aim 
was to investigate immunogenicities and protective efficacies of the immunoglobulin (Ig) M-
degrading enzyme of S. suis, IdeSsuis, in a serotype 9 challenge experiment. 
Materials and methods 
In vitro experiments and experimental challenges in swine were conducted as part of this thesis. This 
included the geno- and phenotyping of 22 S. suis serotype 7 strains and four serotype 9 strains. 
Genotyping was conducted using a multiplex (MP) polymerase chain reaction (PCR), a PCR for 
differentiation of variants of the muramidase-released protein (MRP) gene and multilocus sequence 
typing (MLST). For phenotyping of the S. suis strains, bactericidal assays were carried out which 
served as a model for bacteraemia. This way, susceptibility to S. suis strains and virulence of different 
strains was assessed. Further, through addition of recombinant (r) IdeSsuis, the role of adaptive IgM in 
limiting bacteraemia was elucidated. Western blot analyses were conducted to investigate 
expression and functionality of IdeSsuis as well as expression of MRP in S. suis serotype 7 strains. 
Enzyme-linked immunosorbent assays (ELISA) were used to determine the development of IgM and 
IgG levels in piglets over time and to assess IgG levels following rIdeSsuis immunization. Antigen-
reactive T-helper (h) cells induced by rIdeSsuis immunization were investigated using flow cytometry. 
Finally, two experiments to establish a serotype 7 infection model with 18 and 5 piglets each and two 
vaccination and challenge experiments using different S. suis serotype 9 strains (n=18 piglets/ 
experiment) were conducted. Samples of dissected animals were examined histologically. In one 





Most of the investigated serotype 7 strains belonged to sequence type (ST) 29 which was thus shown 
to be an emerging pathotype in Europe. Despite the close phylogenetic relation of the strains, mrp 
was highly variable. Phenotypically, all strains expressed a small variant of MRP, MRPs. Four selected 
serotype 7 strains were shown to express IdeSsuis with differences in size and functionality. 
Bactericidal assays of these four strains revealed high proliferation in blood of weaning piglets but 
killing in blood of growing piglets of two herds which differed in their S. suis infection status. This 
survival pattern was distinct from a serotype 9 strain. Addition of rIdeSsuis revealed that killing of the 
serotype 7 strains in blood of growing piglets of the infected herd was IgM-mediated. Independent of 
the originating herd, IgM levels of the piglets rose almost synchronous over time. Finally, the 
virulence of a serotype 7 strain was proven in an intravenous challenge experiment with five pigs 
which all developed severe clinical signs of S. suis disease. 
In a vaccination and challenge experiment using a highly virulent serotype 9 strain, immunogenicities 
and protective efficacies of rIdeSsuis immunization were investigated. Nine piglets were prime-boost-
boost vaccinated with rIdeSsuis or placebo-treated and challenged two weeks later. Ninety per cent of 
the placebo-treated piglets developed severe clinical signs of S. suis disease and died or had to be 
euthanized due to animal welfare reasons. All vaccinated piglets survived the experiment, however 
elevated body temperatures and lameness were also noted in this group. Accordingly, rIdeSsuis 
vaccination protected from mortality but not morbidity caused by the challenge strain. 
Seroconversion of the immunized piglets and antigen-reactive Th cells were detected. Neither the 
IgG response nor the Th cell response was boosted through the challenge.  
In a further vaccination and challenge experiment with a different serotype 9 strain, one animal was 
clinically unobtrusive following infection and then developed an acute leptomeningitis on the 11th 
day post infection and had to be euthanized. Dissection of the animal revealed an endocarditis on 
the mitral valve which was proven to be associated with biofilm formation by histology and FISH. In 
addition, a fibrinosuppurative leptomeningitis was diagnosed. The piglet had specific antibodies 
against rIdeSsuis and mediated killing of the challenge strain in a bactericidal assay. 
Conclusions 
In this thesis, I characterized two important pathotypes: S. suis serotype 7 strains of ST29 and a 
highly virulent serotype 9 strain of ST94. The serotype 7 strains represent a distinct pathotype and 
IgM plays a significant role in their control. Following a serotype 9 infection, biofilm formation and a 
subsequent acute leptomeningitis could not be prevented despite blood bactericidal activity and 
opsonizing antibodies. Finally, protection against challenge with a highly virulent serotype 9 strain 
through rIdeSsuis immunization was demonstrated. Thereby, for the first time an antigen was shown 
to confer cross-protection against the important serotypes 2 and 9, which is highly encouraging 
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